{"id":"nitrazepam","rwe":[{"pmid":"41808459","year":"2026","title":"Chronic schizophrenia with aggravation of psychiatric symptoms after cancer surgery: A case report and mini literature review.","finding":"","journal":"Annals of palliative medicine","studyType":"Clinical Study"},{"pmid":"41665171","year":"2026","title":"Comparative effects of hypnotic agents on sleep architecture and respiratory outcomes in obstructive sleep apnea: A systematic review and network meta-analysis.","finding":"","journal":"Psychiatry and clinical neurosciences","studyType":"Clinical Study"},{"pmid":"41045750","year":"2025","title":"A Proof-of-Concept Study on Effectiveness of Nitrazepam in Resistant Infantile Epileptic Spasms Syndrome (NitRIS Trial).","finding":"","journal":"Pediatric neurology","studyType":"Clinical Study"},{"pmid":"40958732","year":"2025","title":"Employing cancer driver genes for the identification of immunological features in two esophageal cancer subtypes to facilitate immunotherapy.","finding":"","journal":"Immunopharmacology and immunotoxicology","studyType":"Clinical Study"},{"pmid":"40921412","year":"2025","title":"Which are the options and dosages for clobazam shortages on epilepsy treatment? Review of literature and survey of specialists.","finding":"","journal":"Arquivos de neuro-psiquiatria","studyType":"Clinical Study"}],"tags":[{"label":"nitrazepam","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"GABA-A receptor alpha-1/beta-2/gamma-2","category":"target"},{"label":"GABRA1","category":"gene"},{"label":"GABRB2","category":"gene"},{"label":"GABRG2","category":"gene"},{"label":"N05CD02","category":"atc"},{"label":"Active","category":"status"},{"label":"Insomnia","category":"indication"},{"label":"Myoclonic seizure","category":"indication"},{"label":"Anti-Anxiety Agents","category":"pharmacology"},{"label":"Anticonvulsants","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"GABA Agents","category":"pharmacology"},{"label":"GABA Modulators","category":"pharmacology"},{"label":"Hypnotics and Sedatives","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":795.566,"date":"","count":224,"signal":"Enthesopathy","source":"DrugCentral FAERS","actionTaken":"Reported 224 times (LLR=796)"},{"llr":723.354,"date":"","count":225,"signal":"Tenosynovitis","source":"DrugCentral FAERS","actionTaken":"Reported 225 times (LLR=723)"},{"llr":694.396,"date":"","count":211,"signal":"Tongue disorder","source":"DrugCentral FAERS","actionTaken":"Reported 211 times (LLR=694)"},{"llr":534.002,"date":"","count":199,"signal":"Tendonitis","source":"DrugCentral FAERS","actionTaken":"Reported 199 times (LLR=534)"},{"llr":497.349,"date":"","count":152,"signal":"Blood parathyroid hormone decreased","source":"DrugCentral FAERS","actionTaken":"Reported 152 times (LLR=497)"},{"llr":476.68,"date":"","count":153,"signal":"Panniculitis","source":"DrugCentral FAERS","actionTaken":"Reported 153 times (LLR=477)"},{"llr":458.414,"date":"","count":138,"signal":"Granuloma skin","source":"DrugCentral FAERS","actionTaken":"Reported 138 times (LLR=458)"},{"llr":451.999,"date":"","count":123,"signal":"Red blood cell sedimentation rate","source":"DrugCentral FAERS","actionTaken":"Reported 123 times (LLR=452)"},{"llr":441.436,"date":"","count":212,"signal":"C-reactive protein abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 212 times (LLR=441)"},{"llr":425.617,"date":"","count":154,"signal":"Skin necrosis","source":"DrugCentral FAERS","actionTaken":"Reported 154 times (LLR=426)"},{"llr":420.842,"date":"","count":154,"signal":"Rheumatoid nodule","source":"DrugCentral FAERS","actionTaken":"Reported 154 times (LLR=421)"},{"llr":406.254,"date":"","count":125,"signal":"Alanine aminotransferase abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 125 times (LLR=406)"},{"llr":341.736,"date":"","count":155,"signal":"Ulcer","source":"DrugCentral FAERS","actionTaken":"Reported 155 times (LLR=342)"},{"llr":323.484,"date":"","count":163,"signal":"Drug eruption","source":"DrugCentral FAERS","actionTaken":"Reported 163 times (LLR=323)"},{"llr":309.974,"date":"","count":154,"signal":"Hypercalcaemia","source":"DrugCentral FAERS","actionTaken":"Reported 154 times (LLR=310)"}],"commonSideEffects":[{"effect":"Enthesopathy","drugRate":"LLR 796","severity":"serious"},{"effect":"Tenosynovitis","drugRate":"LLR 723","severity":"serious"},{"effect":"Tongue disorder","drugRate":"LLR 694","severity":"serious"},{"effect":"Tendonitis","drugRate":"LLR 534","severity":"serious"},{"effect":"Blood parathyroid hormone decreased","drugRate":"LLR 497","severity":"common"},{"effect":"Panniculitis","drugRate":"LLR 477","severity":"common"},{"effect":"Granuloma skin","drugRate":"LLR 458","severity":"common"},{"effect":"Red blood cell sedimentation rate","drugRate":"LLR 452","severity":"common"},{"effect":"C-reactive protein abnormal","drugRate":"LLR 441","severity":"common"},{"effect":"Skin necrosis","drugRate":"LLR 426","severity":"common"},{"effect":"Rheumatoid nodule","drugRate":"LLR 421","severity":"common"},{"effect":"Alanine aminotransferase abnormal","drugRate":"LLR 406","severity":"common"},{"effect":"Ulcer","drugRate":"LLR 342","severity":"common"},{"effect":"Drug eruption","drugRate":"LLR 323","severity":"common"},{"effect":"Hypercalcaemia","drugRate":"LLR 310","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"neozepam","offLabel":[],"synonyms":["nitrazadon","nitrazepam","neozepam","nitrodiazepam"],"timeline":[],"approvals":[],"brandName":"Neozepam","ecosystem":[{"indication":"Insomnia","otherDrugs":[{"name":"amobarbital","slug":"amobarbital","company":""},{"name":"choline","slug":"choline","company":""},{"name":"daridorexant","slug":"daridorexant","company":"Idorsia Pharmaceuticals Ltd"},{"name":"diphenhydramine","slug":"diphenhydramine","company":"Mcneil Cons"}],"globalPrevalence":750000000},{"indication":"Myoclonic seizure","otherDrugs":[{"name":"clonazepam","slug":"clonazepam","company":"Roche"},{"name":"lorazepam","slug":"lorazepam","company":"Valeant Intl"},{"name":"stiripentol","slug":"stiripentol","company":"Biocodex Sa"}],"globalPrevalence":null}],"mechanism":{"target":"GABA-A receptor alpha-1/beta-2/gamma-2","targets":[{"gene":"GABRA1","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-2/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-1"},{"gene":"GABRB2","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-2/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit beta-2"},{"gene":"GABRG2","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-2/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit gamma-2"}],"modality":"Small Molecule","drugClass":"nitrazepam","explanation":"Imagine your brain is like a busy city with lots of people talking and moving around. GABA is like a traffic cop that helps to slow down the traffic and keep everything calm. Neozepam helps the traffic cop to do its job more effectively, which can help to reduce anxiety and seizures.","oneSentence":"Neozepam works by enhancing the activity of the neurotransmitter GABA, which helps to calm down overactive brain activity.","technicalDetail":"Neozepam acts as a positive allosteric modulator of the GABA-A receptor, increasing the frequency of chloride channel opening and enhancing the inhibitory effects of GABA on neuronal excitability."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1945","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NITRAZEPAM","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NITRAZEPAM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:40:49.949647","biosimilars":[],"competitors":[{"drugName":"flurazepam","drugSlug":"flurazepam","fdaApproval":"1970-04-07","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"estazolam","drugSlug":"estazolam","fdaApproval":"1990-12-26","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"triazolam","drugSlug":"triazolam","fdaApproval":"1982-11-15","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"temazepam","drugSlug":"temazepam","fdaApproval":"1981-02-27","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"midazolam","drugSlug":"midazolam","fdaApproval":"1985-12-20","patentExpiry":"Jun 20, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"quazepam","drugSlug":"quazepam","fdaApproval":"1985-12-27","patentExpiry":"Jun 3, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"remimazolam","drugSlug":"remimazolam","fdaApproval":"2020-07-02","patentExpiry":"Nov 7, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"nitrazepam","indications":{"approved":[{"name":"Insomnia","source":"DrugCentral","snomedId":193462001,"regulator":"FDA","usPrevalence":70000000,"globalPrevalence":750000000,"prevalenceMethod":"curated","prevalenceSource":"Sleep Medicine Reviews, 2023"},{"name":"Myoclonic seizure","source":"DrugCentral","snomedId":37356005,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"flurazepam","brandName":"flurazepam","genericName":"flurazepam","approvalYear":"1970","relationship":"same-class"},{"drugId":"estazolam","brandName":"estazolam","genericName":"estazolam","approvalYear":"1990","relationship":"same-class"},{"drugId":"triazolam","brandName":"triazolam","genericName":"triazolam","approvalYear":"1982","relationship":"same-class"},{"drugId":"temazepam","brandName":"temazepam","genericName":"temazepam","approvalYear":"1981","relationship":"same-class"},{"drugId":"midazolam","brandName":"midazolam","genericName":"midazolam","approvalYear":"1985","relationship":"same-class"},{"drugId":"quazepam","brandName":"quazepam","genericName":"quazepam","approvalYear":"1985","relationship":"same-class"},{"drugId":"remimazolam","brandName":"remimazolam","genericName":"remimazolam","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05610969","phase":"PHASE1,PHASE2","title":"Music vs Midazolam During Preop Nerve Block Placement - Part 2 Study On Anxiolytic Options Before Peripheral Nerve Blocks","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2021-09-01","conditions":["Peripheral Nerve Block","Anxiety","Preoperative Anxiety"],"enrollment":36,"completionDate":"2023-05-08"},{"nctId":"NCT04380129","phase":"NA","title":"Music Therapy Model \"The Bonny Method of Guided Imagery and Music\" on Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Thessaly","startDate":"2020-09-01","conditions":["Rheumatoid Arthritis","Quality of Life","Chronic Pain"],"enrollment":74,"completionDate":"2025-02-01"},{"nctId":"NCT03714815","phase":"PHASE2","title":"A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease","status":"TERMINATED","sponsor":"Actelion","startDate":"2018-12-07","conditions":["Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease"],"enrollment":91,"completionDate":"2021-10-12"},{"nctId":"NCT02246634","phase":"NA","title":"Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2014-08","conditions":["Colorectal Neoplasms","Neoplasm Metastases","Hepatic Neoplasms"],"enrollment":282,"completionDate":"2031-12"},{"nctId":"NCT03560297","phase":"NA","title":"SeRenade Parent-Child Music Class Program","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-05-15","conditions":["Autism Spectrum Disorder"],"enrollment":70,"completionDate":"2020-03-20"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT03283956","phase":"","title":"Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-09-13","conditions":["Hepatocellular Carcinoma Non-resectable","Chemoembolization, Therapeutic"],"enrollment":500,"completionDate":"2018-08-31"},{"nctId":"NCT02205931","phase":"PHASE4","title":"Ketogenic Diet in Infants With Epilepsy (KIWE)","status":"UNKNOWN","sponsor":"University College, London","startDate":"2015-01","conditions":["Epilepsy"],"enrollment":160,"completionDate":"2019-06"},{"nctId":"NCT00374777","phase":"PHASE3","title":"A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-08","conditions":["Sleep Initiation and Maintenance Disorders"],"enrollment":450,"completionDate":"2008-06"},{"nctId":"NCT00707915","phase":"PHASE4","title":"Effects of Discontinuation of Benzodiazepine-derivative Hypnotics on Cognitive and Motor Functions in Elderly Persons","status":"COMPLETED","sponsor":"Minamihanno Hospital","startDate":"2008-01","conditions":["Adverse Effects"],"enrollment":30,"completionDate":"2010-07"},{"nctId":"NCT00552526","phase":"PHASE4","title":"Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2007-11","conditions":["Epilepsy","Mental Retardation"],"enrollment":60,"completionDate":"2013-12"},{"nctId":"NCT00004758","phase":"PHASE2","title":"Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1993-11","conditions":["Spasms, Infantile","Epilepsy"],"enrollment":30,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000166923","NDDF":"003484","UNII":"9CLV70W7HS","CHEBI":"CHEBI:7581","INN_ID":"2121","RXNORM":"152070","UMLSCUI":"C0028126","ChEMBL_ID":"CHEMBL13209","KEGG_DRUG":"D00531","DRUGBANK_ID":"DB01595","PUBCHEM_CID":"4506","SNOMEDCT_US":"387449001","MESH_DESCRIPTOR_UI":"D009567"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"26.0 hours","clearance":"0.86 mL/min/kg","bioavailability":"78%","fractionUnbound":"0.13%","volumeOfDistribution":"1.7 L/kg"},"publicationCount":1045,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05CD02","allCodes":["N05CD02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 27","pmid":"41808459","title":"Chronic schizophrenia with aggravation of psychiatric symptoms after cancer surgery: A case report and mini literature review.","journal":"Annals of palliative medicine"},{"date":"2026 Feb 10","pmid":"41665171","title":"Comparative effects of hypnotic agents on sleep architecture and respiratory outcomes in obstructive sleep apnea: A systematic review and network meta-analysis.","journal":"Psychiatry and clinical neurosciences"},{"date":"2025 Dec","pmid":"41045750","title":"A Proof-of-Concept Study on Effectiveness of Nitrazepam in Resistant Infantile Epileptic Spasms Syndrome (NitRIS Trial).","journal":"Pediatric neurology"},{"date":"2025 Oct","pmid":"40958732","title":"Employing cancer driver genes for the identification of immunological features in two esophageal cancer subtypes to facilitate immunotherapy.","journal":"Immunopharmacology and immunotoxicology"},{"date":"2025 Aug","pmid":"40921412","title":"Which are the options and dosages for clobazam shortages on epilepsy treatment? Review of literature and survey of specialists.","journal":"Arquivos de neuro-psiquiatria"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neozepam, also known as nitrazepam, is a small molecule drug that targets the GABA-A receptor alpha-1/beta-2/gamma-2 subunits. It is a member of the benzodiazepine class and is used to treat insomnia and myoclonic seizures. The commercial status of Neozepam is unclear, and it is not FDA-approved. Neozepam has a half-life of 26 hours and a bioavailability of 78%. It is a potent anxiolytic and anticonvulsant agent.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}